Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Momenta Sues Viatris Over Copaxone Generic – Five Years After Launch

Viatris’ Partner Natco: ‘This Is A Meritless Suit’

Executive Summary

One Copaxone (glatiramer acetate) ANDA sponsor is suing another for alleged patent infringement, with Momenta filing a lawsuit against Viatris and its partners in a US district court.

You may also be interested in...



Viatris Keeping Powder Dry On Symbicort With Key Ruling Imminent

In the coming days, Viatris expects to hear back from a court in West Virginia over its legal tussle with AstraZeneca on Symbicort IP. The US-based player has intimated that it may launch the product dependent on the court’s verdict.

Nexavar Rival Offers Natco Opportunity To Build On Lenalidomide Launch

Viatris and Natco have introduced the first US generic version of Nexavar, with the exclusive launch expected to further boost India’s Natco after a healthy financial fourth quarter that was bolstered by revenues from the firm’s recent launch of a Revlimid rival with Teva.

Viatris Sues Teva In US Over ‘Illegal Copaxone Scheme’

Viatris’ Mylan has accused Teva of creating a perfect ‘playbook’ to delay Mylan’s launch of a generic version of its Copaxone blockbuster and then strangle uptake, something Mylan was vocal about years earlier, in a suit filed in a New Jersey court.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel